Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Inca2020on Nov 19, 2020 5:39pm
136 Views
Post# 31937632

RE:Clear, concise and well worth a second read! Bravo AP !

RE:Clear, concise and well worth a second read! Bravo AP !

Keep quoting your alter alias. 

Show me the sales numbers if they're so unique and revolutionary. Presumably there'd be incalls for purchases flooding in. Haven't seen that reflected in the financial statements yet. All I see is FDA approvals and a consistent quarterly loss with negligible earnings, moving timelines, stagnated growth and a declining share price. Tell me what to be excited.

You guys said the stock would be at the moon last January after DIMI got approved?

Where's the price hike? 

I rememeber MM saying, imminent!!  

SouthernTierTom wrote: What does pizza sauce or money losing pizza restaurants have to do with Dialco?  We have 2 FDA approvals for very unique machines (have a look at the presentations on the Spectral site).  We are moving towards getting DIMI approved for home use.    As for the share issue they drove the price from around $0.80 per share to do the issue at $.60 per share.  Since then someone is manipulating the price well below the $0.60.  If you have evidence the institutions that bought are selling please share.  I doubt they are.

Paradigm gave Dialco a value of $150 mill in February before the last FDA approval of DIMI.  That's $0.60 per share Spectral share for Dialco on it's own before the approval.  Outset Medical is worth $2 billion USD and their Tablo machines arguably are not as versatile as Dialco's machines.  On an equivalent basis Dialco would be worth $10 Cdn per Spectral share.  Similarly look at NxStage.  The recent conference and COVID suggest that approved CRRT's are valuable and there's a CRRT shortage.  So we have the goods.  You decide where your opinion on Dialco's value is.  I know where mine is.

Our management is not doing anything (on the surface anyway) to sell machines or promote Dialco.  I think all shareholders share that opinion.  So on Dec 4 grill them about their lack of effort.

 

<< Previous
Bullboard Posts
Next >>